View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBecton Dickinson 将来の成長Future 基準チェック /16現在、 Becton Dickinsonの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報15.4%収益成長率15.51%EPS成長率Medical Equipment 収益成長16.1%収益成長率4.8%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日30 May 2023今後の成長に関する最新情報お知らせ • Aug 04Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the full fiscal year 2023. For the period, Company now expects revenues to be approximately $19.3 billion compared to $19.2 billion to $19.3 billion previously announced. Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture. This reflects an increase of 25 basis points at the mid-point to 7.0%, driven by strong third quarter performance. Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.お知らせ • May 05Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.お知らせ • Feb 04Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022Becton, Dickinson and Company revised revenue guidance for the fiscal year 2022. The company now expects fiscal year 2022 revenues to be in the range of $19.55 billion to $19.75 billion, which reflects an increase of approximately $250 million compared to approximately $19.3 billion to $19.5 billion previously announced.お知らせ • Feb 05Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021Becton, Dickinson and Company revised earnings guidance for the fiscal year 2021. The company now expects fiscal year 2021 revenues to grow 12% to 14% on an as reported basis and 10% to 12% on a currency-neutral basis. This compares to the company’s prior guidance of high single to low double-digit revenue growth on a reported basis.すべての更新を表示Recent updatesお知らせ • Aug 04Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the full fiscal year 2023. For the period, Company now expects revenues to be approximately $19.3 billion compared to $19.2 billion to $19.3 billion previously announced. Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture. This reflects an increase of 25 basis points at the mid-point to 7.0%, driven by strong third quarter performance. Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.お知らせ • Jul 25Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the BoardOn July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company (BD"). Upon joining BD's Board of Directors, Dr. Waldstreicher will serve as a member of both the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board. BD's Board of Directors has determined that Dr. Waldstreicher is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD's Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD's Board of Directors is included under the caption Non-Management Director Compensation" in BD's proxy statement relating to its 2023 Annual Meeting of Shareholders.お知らせ • Jul 23Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion SystemBD (Becton, Dickinson and Company) announced that the updated BD Alaris Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record (EMR) systems. Extending BD's Decades-Long Legacy of Leadership in Infusion Innovation: Today's clearance further enhances BD leadership in the infusion pump market. The updated BD Alaris Infusion system will help empower hospitals and health systems to optimize their workflows and deliver a higher standard of care, which has never been more important than in today's health care environment of staffing shortages and resource constraints. The BD Alaris Infusion System is the only system with a centralized user interface for up to four modules for all major types of infusions, including large volume pumps, syringe pump, and PCA therapy with optional respiratory monitoring. Having one, comprehensive infusion system enables hospitals and health systems to easily scale their infusion needs across an entire integrated delivery network and provide interoperability with EMR interoperability. With a common Point-of-Care Unit, one interface controls all modules, which is different from other pumps on the market that have non-modular architecture. The "one system" approach offers ease, simplicity and scalability. The BD Alaris infusion System also has the breadth of customers, the number of nurses trained on its use and the broadest experience and number of customers with EMR interoperability. Without this type of digital connectivity, clinicians are often required to navigate time-consuming processes, taking multiple steps to manually program infusions. The BD Alaris Inf Fusion System can also feed data to the BD HealthSight™? platform for enterprise medication management, which is a unique combination of connective technologies, analytics and expert services that turn information into insights among caregivers and create seamless visibility across BD medication management solutions. With this platform, health systems can view infusion status in real-time as well as access an intuitive knowledge portal with actionable information related to clinician trends and drug and fluid libraries.お知らせ • Jul 07Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023Becton, Dickinson and Company announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023お知らせ • May 05Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.お知らせ • Feb 09BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination TestBD announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons. The test, for use on the BD MAX Molecular Diagnostic System, uses a single nasal swab or a single nasopharyngeal swab sample to identify and distinguish if a patient has COVID-19, the flu, RSV or some combination of the three, with results available in as little as two hours. The test helps eliminate the need for multiple tests or doctor visits and can help clinicians implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu/RSV season and speed time to diagnosis. The BD MAX System is already in use at thousands of hospitals and laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The Respiratory Viral Panel for BD MAX System is an RT- PCR assay that detects and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV in as little as two hours for the first result, with the simplified and automated workflow of the BD MAX System. Development of this combination test has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority. The BD Respiratory Viral Panel assay for BD MAX System was CE marked under the IVD directive 98/79/EC in May of 2022. It is an important addition to the extensive number of assays available on the system across respiratory infections, sexually transmitted infections, gastrointestinal infections, women's health and health care associated infections. The BD MAX open system allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly.お知らせ • Feb 04Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific DiscoveryBecton, Dickinson and Company announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research. The BD Rhapsody™ HT Xpress System enables scientists to isolate, barcode and analyze single cells at a high sample throughput — up to eight times more cells than prior versions of BD single-cell analyzers. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time. The new technology will be on display at the Advances in Genome Biology and Technology (AGBT) General Meeting February 6-9 in Hollywood, Florida. Single-cell multiomics is a rapidly growing approach that enables researchers to look at multiple layers of "omics" (including genomics, transcriptomics, proteomics and metabolomics) information on a single cell, to exponentially increase the parameters that can be investigated and uncover a more comprehensive view of health and disease. Additionally at the AGBT General Meeting, BD will introduce the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay, a cell receptor profiling tool for single-cell studies, as well as BD® Flex Single-Cell Multiplexing Kits, a companion tool for single-cell studies on any BD Rhapsody system, including the BD Rhapsody™ HT Xpress System, enabling more elements to be measured in a single run by expanding the number of sample tags. BD will also present data on these latest innovations. BD is completing early-access testing for the BD Rhapsody™ HT Xpress System, which will soon be commercially available globally.お知らせ • Jan 25BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023. The indicated annual dividend rate is $3.64 per share.お知らせ • Jan 12Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology LabsBecton, Dickinson and Company introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results. The new BD Kiestra™ 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra™ modules and is scalable to meet labs' unique and evolving needs. With multiple track options and choice of instruments to employ, labs can choose their automation entry point and configure the system to fit their individual workflow and physical lab space. From routine specimen inoculation processes to advanced incubation, imaging and colony selection for pathogen identification, the workflow can be fully automated and is customizable to fit the physical lab space. In addition, each step of the lab's diagnostic pathway is traceable and powered by BD Synapsys™ informatics solution to enable integrated workflows and on-demand insights that help empower laboratory staff to impact turnaround time, expedite laboratory decision-making, improve productivity, and support their compliance requirements.お知らせ • Jan 10Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus DetectionBecton, Dickinson and Company and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX™ System users. The BD MAX™ System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests on the system covering health care associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women's health. As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format. Accordingly, the assay will come in a tube that snaps into the test-specific position on the BD MAX™ ExK™ TNA extraction strip, which is supplied by BD.お知らせ • Jan 07Becton, Dickinson and Company Announces Executive ChangesBecton, Dickinson and Company announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics andcompliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc. and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University. As part of the leadership transition, BD also announced that effective February 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and Public Affairs will report to Simunovich. Inaddition, Corporate Development will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between Corporate Development and Corporate Strategy. Khichi, 55, is currently general counsel and executive vice president, Corporate Development, Public Affairs andRegulatory Affairs, which he has served as since 2017, when he joined BD through the acquisition of C. R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C. R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions.お知らせ • Jan 06Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023Becton, Dickinson and Company announced that they will report Q1, 2023 results at 6:30 AM, US Eastern Standard Time on Feb 02, 2023お知らせ • Dec 21Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023, at 13:00 US Eastern Standard Time. Location: The Biltmore Hotel Miami Coral Gables, 1200 Anastasia Ave, Coral Gables, Florida Florida United States Agenda: To elect as directors of the eleven nominees names attached in the proxy statement doe one year term; to consider the ratification of selection of independent registered public accounting firm; to consider the advisory vote to approve named executive officer compensation; and to discuss other related matters.お知らせ • Feb 04Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022Becton, Dickinson and Company revised revenue guidance for the fiscal year 2022. The company now expects fiscal year 2022 revenues to be in the range of $19.55 billion to $19.75 billion, which reflects an increase of approximately $250 million compared to approximately $19.3 billion to $19.5 billion previously announced.お知らせ • Feb 02Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A.Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A. on February 1, 2022. Cytognos' approximately 80 employees will join BD as a result of the acquisition. The transaction is expected to be immaterial to BD's fiscal 2022 financial results and Cytognos' financial results will be reported under the Biosciences business within the Life Sciences segment. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Cytognos, SL from Vitro S.A. on February 1, 2022.お知らせ • Jan 09Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the BD Kiestra™ Identifa SystemBecton, Dickinson and Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Kiestra™ IdentifA system, which is designed to automate the preparation of microbiology bacterial identification testing. Identifying the microorganism that is causing an infection is a labor-intensive process. With the BD Kiestra™ IdentifA, the lab technician uses BD Synapsys™ informatics to select discrete bacterial colonies from a digital plate image. Sophisticated robotics then physically pick those selected organisms and prepare the sample for specific identification testing. By automating what are typically cumbersome manual steps, the BD Kiestra™ IdentifA may reduce the potential for human error when preparing samples for bacterial identification and produce more accurate diagnoses for patients. Streamlining processes also enables lab technicians to focus their time and expertise on higher-value tasks. BD Kiestra™ IdentifA is the only FDA-cleared solution that is available as part of a track-connected system for lab automation to support specimen preparation workflows for routine and challenging isolate types. The integration of the BD Synapsys™ Informatics solution with the BD Kiestra™ IdentifA, in combination with matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry, can yield more rapid and accurate identification of bacteria and yeasts to aid clinician treatment decisions.お知らせ • Dec 23BD Announces New Distribution and Retail Partners for Bd Veritor At-Home Covid-19 TestBD announced the BD Veritor At-Home COVID-19 Test is now available for purchase through Everly Health, a digital health company at the forefront of the virtual diagnostics-driven care industry, and Southeastern Grocers, parent company of Fresco y Más, Harveys Supermarket, and Winn-Dixie stores, a leading grocery store serving the southeastern United States. Also available for purchase on Amazon.com, the BD Veritor At-Home COVID-19 Test is the first at-home COVID-19 test to use a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Fresco y Más, Harveys Supermarket and Winn-Dixie stores now offer tests to consumers in all in-store pharmacy departments at more than 230 grocery store locations. Everly Health offers tests to businesses, government agencies and consumers through their subsidiaries, Everlywell and Everly Health Solutions. When purchased through Everly Health Solutions, the BD Veritor™ At-Home COVID-19 Test integrates seamlessly with Everly Health Solutions' proprietary COVID-19 platform to give organizations the ability to send at-home tests to individuals, securely view test results for both PCR and rapid tests purchased through the company and help manage all elements of a COVID testing program.お知らせ • Dec 22Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc.Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc. on December 21, 2021. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Scanwell Health, Inc. on December 21, 2021.お知らせ • Dec 18BD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core LabsBD (Becton, Dickinson and Company) announced it has expanded the BD COR™ System to include a new MX instrument for high-throughput molecular testing for infectious diseases. The new instrument and its first test for sexually transmitted infections have been CE marked to the IVD directive 98/79/EC. The new MX instrument is the final piece of the BD COR™ System, which also includes a PX instrument that can prepare diagnostic samples by automating appropriate pre-analytical processing steps and a GX instrument that can leverage the BD Onclarity™ HPV Assay with extended genotyping to screen for HPV infections. The MX instrument is built off the proven BD MAX™ System molecular PCR (polymerase chain reaction) technology platform, a medium-throughput system typically found in hospital labs, and BD intends to leverage the BD MAX™ System menu of infectious disease tests to create assays that can be performed in high-throughput central reference labs on the BD COR™ System. The first test available on the MX instrument is the BD CTGCTV2 for BD COR™ System, which is designed to use a single test to detect the three most prevalent non-viral sexually transmitted infections — Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV). In addition to CE mark, the BD CTGCTV2 for BD COR™ System assay was also included on the Australian Register for Therapeutic Goods (ARTG) following review by Australia's Medical Devices Regulator, the Therapeutic Goods Administration (TGA). The BD COR™ MX/PX System allows 1,700 specimens to be loaded, with onboard capacity for reagents and samples that provide more than six hours of unimpeded system processing and up to 1,000 sample results in 24 hours, eliminating multiple technologist interactions currently required per shift. The BD COR™ System integrates and automates the complete molecular laboratory workflow from sample processing to diagnostic test result. The BD COR™ PX instrument integrates and automates the sample workflow for diagnostic specimens and assays, preparing the samples by performing the appropriate pre-analytical processing steps and automatically delivering the samples to the MX or GX instruments for molecular analysis. The MX instrument will perform the analytical steps of the BD CTGCTV2 molecular assay, including extraction, amplification and detection. Additional assays for the MX module are in development. The GX module is exclusively used for HPV testing. The BD COR™ PX/GX System has been in use in Europe since 2019. The system is modular and scalable, and designed to address multiple needs within laboratories for expanding molecular testing and increasing test volumes. The system is particularly well-suited to laboratories requiring high throughput for sample results and high capacity, minimizing staff interactions. The system enables the processing of samples directly from liquid-based cytology vials and other BD sample collection devices, and the creation of molecular aliquot tubes and assay testing — automating labor-intensive and error-prone manual processes.お知らせ • Dec 10Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd.Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd. on December 9, 2021. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Tissuemed Ltd. on December 9, 2021.お知らせ • Dec 03Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc.Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc. on December 2, 2021. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Venclose, Inc. on December 2, 2021.お知らせ • Aug 26+ 1 more updateBecton, Dickinson and Company Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver ResultsBecton, Dickinson and Company announced the U.S. Food and Drug Administration has issued an Emergency Use Authorization for the BD Veritor™ At-Home COVID-19 Test — the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results. The test does not require a prescription, a laboratory or a long wait for results. BD developed this new rapid, digitally read, lateral flow antigen self-test to make COVID-19 testing faster and easier for people to complete in the privacy and safety of their own homes. The test will initially be made available to businesses, schools and governments looking to provide a self-testing option for employees or students. The BD Veritor™ At-Home COVID-19 Test will use a simple, pain-free nasal swab and an easy-to-use mobile app from Scanwell Health that yields reliable test results in 15 minutes. The app is available on iOS and Android and provides step-by-step instructions on how to collect and transfer the nasal swab sample to the test stick. The mobile device's camera is then used to capture, analyze and interpret the results, which eliminates the human subjectivity of a visually read test. The BD Veritor™ At-Home COVID-19 Test is designed to be easily performed at home by people 14 years of age or older, using Scanwell Health's app to provide clear digital results in 15 minutes. The test can also be used for children as young as two years old with samples collected by an adult. The simple and straightforward testing experience includes a pain-free nasal swab, video instructions that guide users through each step and built-in timers so users can self-test with confidence.お知らせ • Aug 12BD (Becton, Dickinson and Company) Announces the Launch of A New Benchtop Cell AnalyzerBD (Becton, Dickinson and Company) announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes. The new BD FACSymphony™ A1 Cell Analyzer is a fluorescence-activated cell analyzer that offers advanced research capabilities in a compact design, which helps improve access to instrumentation for complex scientific research to more labs. Fluorescence-activated cell sorter (FACS) technology enables the precise isolation of selected single cells from complex samples. This new BD cell analyzer offers researchers and scientists, regardless of their experience and level of expertise, access to proven technology to conduct a variety of flow cytometry experiments, helping them save time by using lab resources more efficiently and expand research capabilities in their own laboratories. This BD FACSymphony™ A1 Cell Analyzer features BD FACSymphony™ instrument technology with the flexibility to meet a broad spectrum of research needs from small particle research to 16-color immunophenotyping, along with industry-standard BD FACSDiva™ Software for streamlined workflows from system setup to data acquisition and analysis. The BD FACSymphony™ A1 Cell Analyzer joins the extended family of BD FACSymphony™ Cell Analyzers and Sorters and is an important addition to this comprehensive line up of flow cytometers to make powerful flow cytometry capabilities more accessible to researchers. The compact size of the system makes it ideal for individual laboratories with limited space. Researchers can perform independent detection of both large and small particles, such as extracellular vesicles on a single instrument using the optional BD® Small Particle Detector. It also enables larger laboratories to perform exploratory experiments without tying up free-standing cell analyzers needed for more complex, longer lead-time experiments.お知らせ • Aug 06Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc.Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc. recently.お知らせ • Jun 24BD Announces Expanded 510(k) Clearance for At-Home System for AscitesBD (Becton, Dickinson and Company) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the PeritX™ Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites. Ascites is a debilitating condition that causes the build-up of fluid in the abdomen. The PleurX™ Peritoneal Catheter System was introduced in 2005 for the drainage of malignant ascites. With the new, expanded indication, the system is being rebranded as the PeritX™ Peritoneal Catheter System to make it easier for physicians to navigate BD's portfolio of at-home drainage products. The PeritX™ Peritoneal Catheter System is the first and only FDA indicated tunneled catheter for the drainage of malignant and non-malignant ascites and for the palliation of symptoms related to recurrent ascites. Ascites is a condition in which fluid collects in spaces within the abdomen. It can make ordinary daily activities more challenging. The fluid may also move to the chest and surround the lungs, making breathing more difficult.お知らせ • May 27Becton, Dickinson and Company Launches Urine Culture ApplicationBecton, Dickinson and Company announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis. Designed using artificial intelligence and leveraging the quality of BD BBL plated media, the application uses digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean caught and catheterized samples. The BD Kiestra system's intelligent incubation and imaging device uses high-throughput robotics to perform time series imaging, coupled with machine learning so that plates with no significant growth can be released for disposal and plates with significant growth automatically go into a queue for clinician analysis. In many labs, urine cultures make up a significant part of the daily workload however, the majority of those samples have no growth or non-significant growth and don't require any additional work-up. Batch review of large volumes of plates with non-significant growth and release can help medical laboratorians focus their time and expertise on more clinically relevant tasks. Powered by BD Synapsys informatics solution, the BD Kiestra Urine Culture application may help improve lab efficiency and enhance quality by providing diagnostically relevant, standardized images for interpretation by laboratory staff. The new Urine Culture app can be used with both standalone BD Kiestra ReadA systems as well as track-based BD Kiestra laboratory automation solutions.お知らせ • May 26+ 1 more updateBecton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC.Becton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC in November 2020. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC in November 2020.お知らせ • May 14Becton, Dickinson and Company Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal SamplesBecton, Dickinson and Company announced the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC. The new claim allows laboratories and facilities to process self-collected samples via a BD diluent tube using the BD Onclarity™ HPV Assay on either the BD Viper™ LT or the BD COR™ System. The BD Viper™ LT is in use globally and the BD COR™ System, launched last year, is in use across Europe. At-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening. Over half of all cervical cancers are diagnosed in women who have never been screened or have not been screened in the previous five yearsii, a situation that has been compounded by the recent global pandemic. Persistent infection with HPV is the cause of virtually all cases of cervical canceriii. Current estimates indicate that every year in Europe, more than 61,000 women are diagnosed with cervical cancer and nearly 26,000 die from the disease,iv making cervical cancer the second-most common female cancer deaths in women aged 15 to 44 and the ninth-most frequent cancer among women overall The BD Onclarity™ HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis and provides genotyping information from specimens collected for cervical cancer screening purposes. The BD Onclarity™ HPV Assay includes genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68 and 56/59/66.お知らせ • May 07+ 1 more updateBD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth MarketsBecton, Dickinson and Company announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes Care business as an independent, publicly traded company(NewCo). BD believes the spinoff of the Diabetes Care business will create long-term value for BD shareholders and create a platform to continue to enhance the tools provided to people with diabetes. The transaction is expected to create two, independent companies with: Enhanced focus on strategic, operational and financial drivers to accelerate revenue growth; Optimized product portfolios to better meet customer and patient needs; More efficient resource and capital allocation to pursue each company's strategic goals. BD management expects that, as a separate independent entity, NewCo will be better positioned to pursue its strategic priorities, build on its current leadership positions in the diabetes care market, and attract new investors. NewCo's margin structure, positive cash flows and anticipated capital structure are expected to provide financial flexibility to pursue increased investments in organic and inorganic growth opportunities. NewCo is also expected to use its publicly traded stock to more effectively attract, incentivize and retain qualified talent. Following the spinoff, BD will maintain category leadership positions across its portfolio in the BD Medical, BD Life Sciences and BD Interventional segments. BD Medical, which includes the Diabetes Care business, will continue to be the global leader in end-to-end medication management solutions with its BD Alaris™ brand of infusion pumps, BD Pyxis™ brand of medication and supply dispensing solutions, BD HealthSight™ data and analytics platforms and its breadth of medication delivery devices. It will also continue to be the global leader in prefilled injectable delivery devices through its innovative pre-fillable syringes, self-injection systems, safety systems and needle technologies. The spinoff does not impact BD's ability to fulfill its orders related to COVID-19 mass vaccination campaigns. BD Life Sciences is a global leader of solutions from discovery to diagnosis, continually advancing science and clinical outcomes across infectious disease and cancer. Its product offerings include market leading specimen collection and management, and microbiology automation and testing solutions. BD is a leading provider of high-quality flow cytometry and single-cell genomics solutions for scientific research and clinical laboratories. The Life Sciences segment continues to play a critical role in both molecular and rapid antigen testing during the COVID-19 pandemic. The BD Interventional segment is also a global leader, advancing the treatment of high-burden diseases like peripheral arterial and venous disease, cancer, and end-stage renal disease. It also focuses on developing innovative surgical, endovascular, urological and critical care interventions that not only meet clinical needs but also deliver value to health systems and improve patients' lives. The decision to pursue the spinoff of the Diabetes Care business demonstrates BD's strong ongoing commitment to the company's BD 2025 strategy, which includes its three strategic pillars of Grow, Simplify and Empower. BD intends to maintain its investment grade rating while investing in growth opportunities focusing on higher growth market categories. BD will also continue to increase its R&D investments and strengthen its pipeline across three innovation themes, which include applying smart devices, robotics, analytics and artificial intelligence to improve care processes; enabling new care settings to enhance patient experience and lower costs; and investing to improve diagnosis and treatment of chronic disease. BD expects the spinoff to be accomplished through a distribution of stock in NewCo to BD shareholders. The spinoff is expected to be tax-free for U.S. federal income tax purposes, except to the extent of any cash received in lieu of fractional shares. BD does not expect the spinoff to impact its current dividend. The transaction is also expected to be completed in the first half of calendar year 2022, subject to the satisfaction of customary conditions, including final approval from the BD Board of Directors, regulatory approvals and the effectiveness of a Form 10 registration statement that will be filed with the SEC. There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed at all.お知らせ • Apr 30+ 1 more updateBD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular FistulaBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV. CONNECT-AV is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQTM EndoAVF System for 24 months. The study's dual primary effectiveness endpoints are the percentage of subjects dialyzing using successful 2-needle cannulation for at least 75% of the dialysis sessions over a continuous 28-day period at 6 months, and the subjects maintaining primary patency at 6 months. The primary safety endpoint is freedom from device and procedure-related serious adverse events through 30 days. The trial is expected to enroll 280 participants in the United States. CONNECT-AV is one of two post-market studies of the WavelinQ™ EndoAVF System. The second study, WAVE-Global is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQ™ EndoAVF System for 24 months. The WAVE-Global primary endpoints are the number of interventions needed post creation to facilitate and/or maintain AV fistula use at 6 months, and the proportion of participants with freedom from Clinical Events Committee adjudicated device- or procedure-related serious adverse events at 30 days. The trial is expected to enroll 150 participants globally (outside of the United States).お知らせ • Apr 29Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2021The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to holders of record on June 9, 2021. The indicated annual dividend rate is $3.32 per share.お知らせ • Apr 27BD Announces FDA 510(k) Submission for BD Alaris™ SystemBD (Becton, Dickinson and Company) announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alaris™ System, the most widely used infusion pump in acute care hospitals across the United States. The 510(k) submission is intended to bring the regulatory clearance for the BD Alaris™ System up to date, implement updated features and address open recall issues, including through a new version of BD Alaris™ System software that will provide clinical, operational and cybersecurity updates. The BD Alaris™ System allows clinicians to deliver medications, fluids and blood products through a single integrated platform that includes large volume pumps, syringe pumps and patient-controlled analgesia (PCA) modules for adult, pediatric and neonatal patients.お知らせ • Mar 11BD Announces Collaboration with ImageMover for Rapid Antigen Test ReportingBD announced an agreement with ImageMover, a software platform that automates and simplifies medical data collection and management, to offer a companion mobile app that enables more streamlined reporting of SARS-CoV-2 antigen testing results performed on the BD Veritor™ Plus System at everyday testing locations, such as schools and businesses. The ImageMover app is available immediately for BD Veritor™ Plus System customers. COVID-19 testing in everyday settings presents challenges in managing test subject demographics and results. The ImageMover app enables organizations performing point-of-care testing to efficiently capture required demographic details of those being tested, upload COVID-19 test results, report results to appropriate stakeholders and automate reporting to federal and state agencies. While the BD Veritor™ Plus System has built-in functionality to allow for data sharing to electronic health records through the BD Synapsys™ Informatics platform, that functionality requires an information technology infrastructure common to diagnostic testing locations in health care facilities such as hospitals, doctor's offices and urgent care centers. The addition of the ImageMover app provides the benefits of seamless and secure data sharing for everyday locations that don't have a health care information technology platform in place. The ImageMover app coordinates with the BD Veritor™ Plus System to upload testing results for streamlined reporting and significantly reduced manual documentation. The app is compliant with patient privacy requirements under the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For traditional acute care settings, the optional BD Synapsys™ Informatics solution will continue to deliver automated result reporting, provide streamlined CARES Act and other Health & Human Services-mandated reporting functionality, and offer analytics and reports to support clinical and operational decision-making. The ImageMover app differs from BD's previously announced collaboration with Scanwell Health, which was created to develop a lateral flow antigen test to be paired with the Scanwell Health mobile app for at-home use. The Scanwell Health app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample, perform the test and use the mobile device's camera to analyze and interpret results in the home. The ImageMover app still requires the use of the BD Veritor™ Plus System to read the results of the test, but it provides a more streamlined reporting tool for testing locations that don't have a health care IT infrastructure.お知らせ • Mar 05Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc.Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc. on March 4, 2021. BD will look forward to welcoming GSL's approximately 20 full-time associates, headquartered in Vancouver, Washington. Andy Dixon, Taylor Will and Michael Mahoney of Harris Williams LLC acted as financial advisor to GSL Solutions in the transaction. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of GSL Solutions, Inc. on March 4, 2021.お知らせ • Feb 23BD and Scanwell Health Announces Collaboration for At-Home Rapid Test for COVID-19BD (Becton, Dickinson and Company) and Scanwell Health announced a collaboration to create an at-home rapid test for SARS-CoV-2 using a BD antigen test and the Scanwell Health mobile app. As part of the collaboration, BD plans to produce a lateral flow antigen test and pair it with the Scanwell Health mobile app. The app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample and use the mobile device's camera to analyze and interpret results. The test result will be displayed onscreen, and the companies are also planning to develop functionality to assist in automated reporting to public health agencies. This approach is intended to provide an efficient and scalable rapid antigen home testing solution. BD has been on the forefront of the COVID-19 response providing innovative solutions for immunology research, molecular- and antigen-based diagnostics, devices that aid in therapeutics and injection devices for vaccine administration.お知らせ • Feb 13BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single TestBD (Becton, Dickinson and Company) announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and Influenza A+B that can return results in two to three hours. The new test also has been CE marked to the IVD Directive (98/79/EC). The new EUA includes updated information in the test's instructions for use that addresses variants of the SARS-COV-2 virus, including variants from the U.K. and South Africa. A computer analysis showed that 99.9% of the genetic sequences of the these variants are an identical match to at least one of the two molecular targets for the testi. This ability to detect these new variants also applies to the standalone SARS-CoV-2 test for the BD MAX™ System. The BD® SARS-CoV-2/Flu assay is run on the BD MAX™ System and distinguishes between SARS-CoV-2 and Influenza A+B, providing a positive or negative result for each virus using a single specimen. The BD MAX™ System, a molecular diagnostic platform, is already in use at thousands of laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The BD® SARS-CoV-2/Flu for BD MAX™ System kits are now available for order in the United States and Europe. The test is the latest addition to the company's comprehensive COVID-19 diagnostics response. In October 2020, BD announced the CE mark for the CerTest Biotec VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit, which allows BD MAX™ System users to combine as a single test the VIASURE Flu A, Flu B & Respiratory Syncytial Virus (RSV) Real Time PCR Detection Kit and report concurrently. This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection of nucleic acid from SARS CoV-2, influenza A virus and influenza B virus and not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.お知らせ • Feb 05Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021Becton, Dickinson and Company revised earnings guidance for the fiscal year 2021. The company now expects fiscal year 2021 revenues to grow 12% to 14% on an as reported basis and 10% to 12% on a currency-neutral basis. This compares to the company’s prior guidance of high single to low double-digit revenue growth on a reported basis.お知らせ • Feb 02Becton, Dickinson and Company Announces New Clinical Data Found Robust Evidence Using A Vascular Care SolutionBD (Becton, Dickinson and Company) announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs). The results of the CLEAN3 trial1, published in The Lancet Infectious Diseases, showed the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%, respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively). PIVC failure was defined as any premature removal of PIVC before end of treatment – other than for routine replacement – and included phlebitis, infiltration, occlusion, dislodgment, local infection and catheter-related bloodstream infection (whichever occurred first). The CLEAN3 trial also evaluated skin antiseptics with 2% chlorhexidine-gluconate (CHG) 70% isopropyl alcohol (IPA) single use, sterile applicator versus 5% povidone iodine (PVI) 69% ethanol applied with sterile gauze in preventing infectious complications related to the use of PIVCs (catheter colonization: 0.9% vs. 16.9%, respectively; local infection: 0% vs. 1.2%, respectively). The trial, which involved approximately 1,000 patients from nine different medical wards within a single university hospital (Poitiers University Hospital, France), evaluated PIVC failure rates by comparing the BD vascular care solution for PIVCs, which included an integrated PIVC (BD Nexiva™), a positive displacement needle-free connector (BD MaxZero™), a disinfecting cap (BD PureHub™) and a sterile prefilled flush syringe (BD PosiFlush™) – compared with a standard group, which included a straight safety PIVC (BD Insyte™ Autoguard™ BC Winged), extension set three-way stopcock; the PIVCs were continuously infused with saline or polyionic solution, by gravity.お知らせ • Jan 28+ 1 more updateBecton, Dickinson and Company Announces Board ChangesBD (Becton, Dickinson and Company) announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, effective April 28, 2021. Polen will succeed Vincent A. Forlenza, who will retire from BD at that time. Polen joined BD in 1999, and has held a variety of leadership roles at numerous business units. He was appointed president of BD in April 2017, was named chief operating officer in October 2018 and became CEO in January 2020.お知らせ • Jan 26Becton, Dickinson and Company Announces the Publication of Peer-Reviewed Study That Shows Antigen Test May Be More Selective Than Polymerase Chain Reaction Molecular TestsBecton, Dickinson and Company announced the publication of a peer-reviewed study that shows BD's antigen test may be more selective than PCR (polymerase chain reaction) molecular tests at detecting people who are contagious and able to spread COVID-19 disease. The study compared antigen and PCR test results to positive results using a viral cell culture test. Viral growth in the cell culture test indicates the presence of live virus in the patient sample, which may indicate the presence of infectious virus at the time the sample was taken. If no growth is present in the viral cell culture test, it is likely that there wasn't enough viable virus for the patient to be contagious at the time the sample was taken. Out of 38 positive PCR result specimens tested, only 28 were positive using the cell culture technique. The antigen tests, conducted using the BD Veritor™ Plus System, were positive in 27 of the 28 cell culture positive tests. This data suggests that 10 of the 38 PCR positive results were potentially identifying non-infectious individuals, meaning PCR detected viral RNA fragments or small amounts of intact SARS-CoV-2 virus and that the patient wasn't actually contagious at the time the sample was taken. However, the BD antigen test agreed with all but one cell culture positive test. Diagnosing and isolating contagious people has been the primary goal for testing during the pandemic, followed by contact tracing and testing.お知らせ • Jan 13Becton, Dickinson and Company to Report Q1, 2021 Results on Feb 04, 2021Becton, Dickinson and Company announced that they will report Q1, 2021 results on Feb 04, 2021お知らせ • Dec 19Becton, Dickinson and Company, Annual General Meeting, Jan 26, 2021Becton, Dickinson and Company, Annual General Meeting, Jan 26, 2021, at 13:00 US Eastern Standard Time. Agenda: To consider the election as directors of the thirteen nominees named in the attached proxy statement for a one-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; to consider a shareholder proposal seeking to lower the ownership threshold required to call a special shareholders meeting, if properly presented at the meeting; and to consider such other business as may properly come before the meeting, or any adjournment or postponement thereof.お知らせ • Dec 18+ 2 more updatesBecton, Dickinson and Company Surpasses 1 Billion Injection Device Orders in Support of Covid-19 Vaccination Efforts Around the WorldBD announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to support global COVID-19 vaccination planning efforts. This milestone reflects 400 million dose units committed to countries across Europe, including Belgium, France, Germany, Netherlands, Spain and the United Kingdom, among several others. It also reflects governments around the world, including the United States, Australia, Canada and Saudi Arabia, as well as non-governmental organizations supporting vaccine deployment for developing countries. Shipments are already underway and more than 300 million injection devices have been delivered around the world to date, including 125 million in Europe, with the remaining orders to be delivered between now and the end of 2021 to support vaccine administration. A vast majority of the needles and syringes for Europe are being produced in two of BD's manufacturing facilities in Europe. These devices are then shipped to governments or appointed distribution partners where they will then be distributed to health care facilities based on each country's individual distribution and allocation strategy. BD continues to be in discussions with governments and non-governmental organizations on the need to place orders immediately for delivery later in calendar year 2021 and 2022. The company continues to closely plan supply capabilities to ensure maximum volumes can be dedicated to COVID-19 efforts while minimizing disruption for routine health care and annual flu vaccination and childhood immunization programs. In addition to supporting immediate efforts for COVID-19 vaccination readiness, BD is also working on multiple fronts to help ensure the global community is prepared for future pandemic vaccination efforts by: Partnering with the U.S. government on a $70 million capital project to further expand BD's operations and manufacturing capacity in Nebraska. The new capacity is expected to be online in summer 2021 and once completed, the federal government will have priority access to hundreds of millions of injection devices to support vaccination efforts for COVID-19 and future pandemics. Investing approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems across its six global manufacturing locations and add a new manufacturing facility in Europe. This will allow for continued growth of new injectable drugs and vaccines, but also provide surge capacity for increased pre-fillable syringe demand during times of pandemic response. Actively engaging with med-tech associations and research groups to address challenges, solutions and further innovation in support of a more sustainable future vaccine ecosystem. In addition to ramping up manufacturing of needles and syringes, BD has been working closely with governments and multilateral organizations around the world to expand access to diagnostic testing and support treatment of COVID-19 patients. The company has supplied health care providers globally with millions of products used in of the fight against COVID-19, including swabs for flu and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus System, infusion pumps, infusion sets and catheters. BD Biosciences instruments are also being used by researchers around the world to better understand the human immune response to COVID-19.お知らせ • Nov 18Becton, Dickinson and Company Announces Board ChangesOn November 13, 2020, Patrick K. Kaltenbach, Executive Vice President and President, Life Sciences Segment of Becton, Dickinson and Company (BD"), informed BD that he plans to leave BD, effective January 21, 2021, to pursue an executive leadership position based in Europe, bringing him closer to his family. As previously announced, Dave Hickey, currently President of BD's Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President, Life Sciences Segment, effective January 1, 2021. BD had previously announced plans to have Mr. Kaltenbach serve as BD's Chief Technology Officer, beginning January 1, 2021. As a result of Mr. Kaltenbach's upcoming departure from BD, John DeFord, Executive Vice President and Chief Technology Officer, will postpone his previously announced retirement and continue to lead the company's innovation strategy and R&D pipeline until May 28, 2021 or earlier when a successor is identified.お知らせ • Nov 13Becton, Dickinson and Company (NYSE:BDX) acquired Medical Business assets of Cubex LLC.Becton, Dickinson and Company (NYSE:BDX) acquired Medical Business assets of Cubex LLC on November 12, 2020. Becton, Dickinson and Company is excited to welcome approximately 40 Cubex LLC associates into the BD family. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Medical Business assets of Cubex LLC on November 12, 2020.お知らせ • Nov 11+ 1 more updateBD Announces Canadian Government Order of More Than 7 Million Portable, Rapid Point-of-Care Antigen Tests to Detect SARS-CoV-2 in 15 minutesBD announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been authorized for use by Health Canada under Interim Order. This authorization has been accompanied by an order from the Canadian government for 7.6 million tests through March 2021 to support Canada's planning for an advanced COVID-19 testing strategy. The new test delivers results in approximately 15 minutes on an easy to use, portable instrument, which is a critical improvement in turnaround time for COVID-19 diagnostics, because it provides real time results and enables decision making while the patient is still onsite. This test is designed to be performed at the point-of-care, reducing the burden on testing laboratories. The test uses a mid-nasal swab to collect patient samples, which is less invasive for the patient than nasopharyngeal sample collection. The test, which received Health Canada authorization in early October, has been available in the United States since July through an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). The test uses the BD Veritor™ Plus System, which is already in use in Canada to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. The BD Veritor™ Plus System, which has a slightly larger footprint than a mobile phone, offers an easy-to-use workflow that makes it an ideal solution for point-of-care settings. It also offers customers traceability and reporting capabilities through the optional BD Synapsys™ informatics solution. BD has also been supporting SARS-CoV-2 molecular testing (RT-PCR) in Canadian labs on the BD MAX™ System.お知らせ • Nov 04Becton, Dickinson and Company Receives Order from Dutch Ministry of Health for More Than 9 Million 15-Minute Covid-19 Antigen TestsBecton, Dickinson and Company announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid, point-of-care, SARS-CoV-2 antigen tests for use on the BD Veritor™ Plus System, which detects SARS-CoV-2 in symptomatic patients in approximately 15 minutes. The first 1.2 million units will be delivered by mid-November. This is the first government contract in Europe for this test, which was CE marked to the IVD Directive (98/79/EC) in September. The Dutch Ministry of Health increased its initial order by 8 million assays to improve testing capacity. BD expects the order to be fulfilled by June 2021. The BD Veritor™ Plus System is a portable, easy-to-use device that makes it an ideal solution for point-of-care settings. The BD Veritor™ Plus System is already in use across Europe to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. The SARS-CoV-2 assay has been available in the United States since July through an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).お知らせ • Oct 06FDA 510(k) Clearance for BD Facslyric Flow Cytometer with Newly Integrated BD Facsduet Sample Preparation SystemBecton, Dickinson and Company announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ Flow Cytometer with the Integrated BD FACSDuet™ Sample Preparation System. The new integrated system enables clinical laboratories to fully automate the sample to answer process and improve their efficiency by reducing errors and limiting the manual user interactions required to run assays on the BD FACSLyric™ Flow Cytometer. The BD FACSDuet™ Sample Preparation System builds new capabilities into the BD portfolio of clinical flow cytometry solutions offering a pre-analytical system, that combined with the BD FACSLyric™ Flow Cytometer is the first truly walkaway sample-to-answer solution for clinical labs. Physical integration between the BD FACSDuet™ Sample Preparation System and the BD FACSLyric™ Flow Cytometer allows technicians to load samples and reagents onto the BD FACSDuet™ Sample Preparation System and obtain results once the samples are acquired and analyzed on the BD FACSLyric™ Flow Cytometer. Data integration using the BD FACSLink™ Middleware Solution offers bidirectional communication between the instruments and connectivity with laboratory information systems (LIS). Automation solutions for flow cytometry such as the BD FACSDuet™ and BD FACSLyric™ Complete Sample-to-Answer Solution helps to improve accuracy and standardization from instrument-to-instrument and operator-to-operator, enhancing throughput and providing consistent results that clinicians depend on to inform patient care.お知らせ • Oct 03Becton, Dickinson and Company to Report Q4, 2020 Results on Nov 05, 2020Becton, Dickinson and Company announced that they will report Q4, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020お知らせ • Oct 01Becton, Dickinson and Company Announces CE Mark of Portable, Rapid Point-Of-Care Antigen Test to Detect SARS-CoV-2 in 15 MinutesBecton, Dickinson and Company announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the IVD Directive (98/79/EC). The new test delivers results in 15 minutes on an easy-to-use, portable instrument, which is a critical improvement in turnaround time for COVID-19 diagnostics, because it provides real-time results and enables decision-making while the patient is still onsite. The company expects commercial availability of this new assay at the end of October for countries in Europe that recognize the CE mark. The test, which has been available in the United States since July through an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA), uses the BD Veritor™ Plus System, which is already in use across Europe to test for conditions such as Group A Strep, influenza A+B and Respiratory Syncytial Virus (RSV). The BD Veritor™ Plus System, which is slightly larger than a mobile phone, offers an easy-to-use workflow that makes it an ideal solution for point-of-care settings. It also offers customers traceability and reporting capabilities through the optional BD Synapsys™ informatics solution. The European Centre for Disease Prevention and Control (ECDC) recently released guidance that all patients with acute respiratory symptoms should be tested for both SARS-CoV-2 and influenza A+B in parallel during flu season1. The BD Veritor™ Plus System can test for both infections on the same platform. BD is leveraging its global manufacturing network and scale to produce 8 million SARS-CoV-2 antigen tests per month by October and expects to produce 12 million tests per month by March 2021. All BD SARS-CoV-2 diagnostic products have regulatory authorizations in the markets where they are sold. European customers interested in BD diagnostic solutions for SARS-CoV-2 should visit bd.com/VeritorSystem-EU [1] or contact BD's local customer service. The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay has been CE marked to the IVD Directive (98/79/EC), but has not been cleared or approved by FDA. The test has been authorized by FDA under an EUA for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers or for at-home use.お知らせ • Sep 24BD Submits Pre-Market Approval Supplement to the U.S. Food and Drug Administration for the use of the ThinPrep® Pap Test™ PreservCyt® SolutionBD announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep® Pap Test™ PreservCyt® Solution vial as an approved sample type for its BD Onclarity™ HPV Assay. The PMA supplement would expand the sample claims that can be used in addition to the BD SurePath™ vial for the detection of human papillomavirus (HPV) using the BD Onclarity™ HPV Assay. The submission includes performance data for the BD Viper™ LT and the BD COR™ Systems. An additional supplement was submitted in January 2020 to seek approval for the BD Onclarity™ HPV assay on the BD COR™ System and the BD SurePath™ Liquid Based Cytology vial.お知らせ • Sep 22Becton, Dickinson and Company Announces FDA Classifications for August 4th Recalls of BD Alaris System Hardware for Keypads, Incorrect Module Types And/Or Sizes, and Channel ErrorBecton, Dickinson and Company provided an update on previously announced voluntary recalls of the BD Alaris System. Three of the recalls, which BD announced on Aug. 4, 2020, have been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means that FDA has determined that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. One of the situations was designated as a Class II recall, which means use of the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. This FDA classification does not change the guidance BD provided in the company's Aug. 4th recall announcements to customers. BD initiated the voluntary recalls to notify customers of the potential for four hardware situations that may result in the infusion pump not operating as expected. BD has provided instructions to correct and/or mitigate the situations. The four recalls include: Alaris PC Unit Model 8015 Front Case with Keypad Replacement Kits (Recall 1 'Class I): The pump module keypad may exhibit keys that are unresponsive or stuck as a result of fluid ingress, potentially resulting in a delay to the start of infusion, interruption of infusion or inability to titrate medication. Alaris Pump Module Model 8100 Front Case with Keypad Replacement Kits (Recall 2 'Class I): Pump Module keypad may exhibit keys that are unresponsive or stuck as a result of fluid ingress, potentially resulting in a delay to the start of infusion or interruption of infusion. BD Alaris Syringe Module Model 8110 and PCA Module Model 8120 (Recall 3 - Class I): The Alaris PC unit may display incorrect syringe type and/or syringe sizes. This could potentially result in delays in infusion, under-infusion or over-infusion. BD Alaris EtCO2 Module model 8300 channel error (Recall 4 'Class II). Infusion pump component defect may result in interruption of patient monitoring. Affected Products: Recall 1: BD Alaris PC Unit model 8015 (manufactured from April 7, 2017 to present). PC Unit Front Case with Keypad Replacement Kits: TC10008389 ASSY CASE FRONT W/KEYPAD 8015LS; TC10010217 ASSY FRT CASE W/KEYPAD 8015 M2; TC10012515 ASSY FR CASE W/KEYPAD 8015 M2; TC10013702 ASSY, CASE, FRONT W/KEYPAD, 8015LS; TC10013664 ASSY FR CASE W/KEYPAD 8015 M2. Recall 2: BD Alaris Pump Module Model 8100 (manufactured from December 1, 2016 to January 23, 2019); Pump Module Door Assembly Replacement Kits (labeled with a date prior to January 25, 2019); Affected part numbers: 49000239; 49000346; 49000438; 49000439. Recall 3: BD Alaris Syringe Module Model 8110 (manufactured from March 1, 2010 to present); BD Alaris PCA Module Model 8120 (manufactured from March 1, 2010 to present); Syringe/PCA Sizer Sensor Replacement Kit (manufactured from March 1, 2010 to present); Affected part number: 12278652. Recall 4: Alaris EtCO2 Module, Model 8300 (manufactured from January 5, 2018 to January 4, 2019). Note that some affected devices may be branded under the CareFusion name.お知らせ • Jul 31Becton, Dickinson and Company (NYSE:BDX) acquired Straub Medical AG.Becton, Dickinson and Company (NYSE:BDX) acquired Straub Medical AG on April 20, 2020. Martin Frey, Dennis Gödde, Yves Sewo and Andrina Schmitz of PwC Corporate Finance Switzerland acted as a financial advisors to the shareholders of Straub Medical AG. Daniel Daeniker, Daniel Hasler, Stefan Oesterhelt, Luca Dal Molin, Richard Stäub, Katrin Ivell and Claudia Suter of Homburger AG acted as legal advisors to Becton, Dickinson and Company. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Straub Medical AG on April 20, 2020.お知らせ • Jul 04Becton, Dickinson and Company(NYSE:BDX) dropped from Russell 1000 Growth-Defensive IndexBecton, Dickinson and Company(NYSE:BDX) dropped from Russell 1000 Growth-Defensive Index業績と収益の成長予測NYSE:BDXB - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202521,5102,9733,9165,081109/30/202420,3442,4573,9024,666159/30/202319,2582,0873,8724,134153/31/202318,8091,5561,1442,101N/A12/31/202218,7381,4861,4962,494N/A9/30/202218,8701,5451,7962,769N/A6/30/202218,9581,4131,4652,575N/A3/31/202218,9241,4302,0413,141N/A12/31/202118,5341,0792,6203,751N/A9/30/202119,1311,5143,4164,610N/A6/30/202119,0661,4864,2225,177N/A3/31/202118,3131,3794,1505,064N/A12/31/202018,2071,5073,4764,359N/A9/30/202016,0742452,7283,497N/A6/30/202016,9177862,4743,429N/A3/31/202017,4149232,5093,499N/A12/31/201917,3557602,8353,798N/A9/30/201917,2901,0812,3733,330N/A6/30/201917,1087842,3593,265N/A3/31/201917,0369262,0092,875N/A12/31/201817,0638941,9062,790N/A9/30/201815,9831591,9702,865N/A6/30/201814,7476211,8372,685N/A3/31/201813,503-991,6812,527N/A12/31/201712,2512941,7622,555N/A9/30/201712,0931,0301,8232,550N/A6/30/201712,1587591,3742,129N/A3/31/201712,3211,3141,8722,579N/A12/31/201612,4191,309N/A2,411N/A9/30/201612,483976N/A2,559N/A6/30/201612,3121,139N/A2,532N/A3/31/201612,234810N/A2,236N/A12/31/201511,217688N/A1,907N/A9/30/201510,282695N/A1,730N/A6/30/20159,410815N/A1,591N/A3/31/20158,4481,079N/A1,492N/A12/31/20148,4681,150N/A1,677N/A9/30/20148,4461,185N/A1,746N/A6/30/20148,345974N/A1,876N/A3/31/20148,239941N/A1,830N/A12/31/20138,169930N/A1,626N/A9/30/20138,054929N/A1,505N/A6/30/20137,9201,114N/A1,405N/A3/31/20137,8481,132N/A1,595N/A12/31/20127,7761,131N/A1,679N/A9/30/20127,7081,110N/A1,760N/A6/30/20127,7291,120N/A1,733N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BDXBの予測収益成長率 (年間15.4% ) は 貯蓄率 ( 2.1% ) を上回っています。収益対市場: BDXBの収益 ( 15.4% ) US市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: BDXBの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: BDXBの収益 ( 4.8% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: BDXBの収益 ( 4.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BDXBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/06/02 01:16終値2023/05/31 00:00収益2023/03/31年間収益2022/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Becton, Dickinson and Company 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。35 アナリスト機関David ToungArgus Research CompanyAdam FeinsteinBarclaysMatthew MiksicBarclays32 その他のアナリストを表示
お知らせ • Aug 04Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the full fiscal year 2023. For the period, Company now expects revenues to be approximately $19.3 billion compared to $19.2 billion to $19.3 billion previously announced. Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture. This reflects an increase of 25 basis points at the mid-point to 7.0%, driven by strong third quarter performance. Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.
お知らせ • May 05Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.
お知らせ • Feb 04Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022Becton, Dickinson and Company revised revenue guidance for the fiscal year 2022. The company now expects fiscal year 2022 revenues to be in the range of $19.55 billion to $19.75 billion, which reflects an increase of approximately $250 million compared to approximately $19.3 billion to $19.5 billion previously announced.
お知らせ • Feb 05Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021Becton, Dickinson and Company revised earnings guidance for the fiscal year 2021. The company now expects fiscal year 2021 revenues to grow 12% to 14% on an as reported basis and 10% to 12% on a currency-neutral basis. This compares to the company’s prior guidance of high single to low double-digit revenue growth on a reported basis.
お知らせ • Aug 04Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the full fiscal year 2023. For the period, Company now expects revenues to be approximately $19.3 billion compared to $19.2 billion to $19.3 billion previously announced. Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture. This reflects an increase of 25 basis points at the mid-point to 7.0%, driven by strong third quarter performance. Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.
お知らせ • Jul 25Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the BoardOn July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company (BD"). Upon joining BD's Board of Directors, Dr. Waldstreicher will serve as a member of both the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board. BD's Board of Directors has determined that Dr. Waldstreicher is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD's Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD's Board of Directors is included under the caption Non-Management Director Compensation" in BD's proxy statement relating to its 2023 Annual Meeting of Shareholders.
お知らせ • Jul 23Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion SystemBD (Becton, Dickinson and Company) announced that the updated BD Alaris Infusion System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), which enables both remediation and a return to full commercial operations for the most comprehensive infusion system available in the United States. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with the most widely used electronic medical record (EMR) systems. Extending BD's Decades-Long Legacy of Leadership in Infusion Innovation: Today's clearance further enhances BD leadership in the infusion pump market. The updated BD Alaris Infusion system will help empower hospitals and health systems to optimize their workflows and deliver a higher standard of care, which has never been more important than in today's health care environment of staffing shortages and resource constraints. The BD Alaris Infusion System is the only system with a centralized user interface for up to four modules for all major types of infusions, including large volume pumps, syringe pump, and PCA therapy with optional respiratory monitoring. Having one, comprehensive infusion system enables hospitals and health systems to easily scale their infusion needs across an entire integrated delivery network and provide interoperability with EMR interoperability. With a common Point-of-Care Unit, one interface controls all modules, which is different from other pumps on the market that have non-modular architecture. The "one system" approach offers ease, simplicity and scalability. The BD Alaris infusion System also has the breadth of customers, the number of nurses trained on its use and the broadest experience and number of customers with EMR interoperability. Without this type of digital connectivity, clinicians are often required to navigate time-consuming processes, taking multiple steps to manually program infusions. The BD Alaris Inf Fusion System can also feed data to the BD HealthSight™? platform for enterprise medication management, which is a unique combination of connective technologies, analytics and expert services that turn information into insights among caregivers and create seamless visibility across BD medication management solutions. With this platform, health systems can view infusion status in real-time as well as access an intuitive knowledge portal with actionable information related to clinician trends and drug and fluid libraries.
お知らせ • Jul 07Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023Becton, Dickinson and Company announced that they will report Q3, 2023 results at 9:30 AM, US Eastern Standard Time on Aug 03, 2023
お知らせ • May 05Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023Becton, Dickinson and Company raised earnings guidance for the fiscal year 2023. For the year, the company expected revenues to be in the range of approximately $19.2 billion to $19.3 billion compared to $19.1 billion to $19.3 billion previously announced, which reflects an increase of approximately $50 million at the mid-point. Revenue guidance now assumes base business currency-neutral revenue growth of 6.5% to 7.0% compared to 5.75% to 6.75% previously announced, which represents an increase of 50 basis points, or approximately $90 million at the mid-point. Revenue guidance now assumes approximately $50 million in COVID-only diagnostic testing revenues, compared to approximately $50 million to $100 million previously announced. Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.
お知らせ • Feb 09BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination TestBD announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons. The test, for use on the BD MAX Molecular Diagnostic System, uses a single nasal swab or a single nasopharyngeal swab sample to identify and distinguish if a patient has COVID-19, the flu, RSV or some combination of the three, with results available in as little as two hours. The test helps eliminate the need for multiple tests or doctor visits and can help clinicians implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu/RSV season and speed time to diagnosis. The BD MAX System is already in use at thousands of hospitals and laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The Respiratory Viral Panel for BD MAX System is an RT- PCR assay that detects and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV in as little as two hours for the first result, with the simplified and automated workflow of the BD MAX System. Development of this combination test has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority. The BD Respiratory Viral Panel assay for BD MAX System was CE marked under the IVD directive 98/79/EC in May of 2022. It is an important addition to the extensive number of assays available on the system across respiratory infections, sexually transmitted infections, gastrointestinal infections, women's health and health care associated infections. The BD MAX open system allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly.
お知らせ • Feb 04Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific DiscoveryBecton, Dickinson and Company announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research. The BD Rhapsody™ HT Xpress System enables scientists to isolate, barcode and analyze single cells at a high sample throughput — up to eight times more cells than prior versions of BD single-cell analyzers. The system ensures no sample loss and gives scientists the flexibility to analyze multiple samples and different cell sizes and types, such as stem cells or cancer cells, at the same time, to obtain more insights in less time. The new technology will be on display at the Advances in Genome Biology and Technology (AGBT) General Meeting February 6-9 in Hollywood, Florida. Single-cell multiomics is a rapidly growing approach that enables researchers to look at multiple layers of "omics" (including genomics, transcriptomics, proteomics and metabolomics) information on a single cell, to exponentially increase the parameters that can be investigated and uncover a more comprehensive view of health and disease. Additionally at the AGBT General Meeting, BD will introduce the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay, a cell receptor profiling tool for single-cell studies, as well as BD® Flex Single-Cell Multiplexing Kits, a companion tool for single-cell studies on any BD Rhapsody system, including the BD Rhapsody™ HT Xpress System, enabling more elements to be measured in a single run by expanding the number of sample tags. BD will also present data on these latest innovations. BD is completing early-access testing for the BD Rhapsody™ HT Xpress System, which will soon be commercially available globally.
お知らせ • Jan 25BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023. The indicated annual dividend rate is $3.64 per share.
お知らせ • Jan 12Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology LabsBecton, Dickinson and Company introduced a new, robotic track system for the BD Kiestra™ microbiology laboratory solution that automates lab specimen processing, which may help to reduce manual labor and wait time for results. The new BD Kiestra™ 3rd Generation Total Lab Automation System allows laboratories to create a custom and flexible total lab automation configuration to connect multiple BD Kiestra™ modules and is scalable to meet labs' unique and evolving needs. With multiple track options and choice of instruments to employ, labs can choose their automation entry point and configure the system to fit their individual workflow and physical lab space. From routine specimen inoculation processes to advanced incubation, imaging and colony selection for pathogen identification, the workflow can be fully automated and is customizable to fit the physical lab space. In addition, each step of the lab's diagnostic pathway is traceable and powered by BD Synapsys™ informatics solution to enable integrated workflows and on-demand insights that help empower laboratory staff to impact turnaround time, expedite laboratory decision-making, improve productivity, and support their compliance requirements.
お知らせ • Jan 10Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus DetectionBecton, Dickinson and Company and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX™ System users. The BD MAX™ System is a fully integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers an extensive menu of tests on the system covering health care associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women's health. As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format. Accordingly, the assay will come in a tube that snaps into the test-specific position on the BD MAX™ ExK™ TNA extraction strip, which is supplied by BD.
お知らせ • Jan 07Becton, Dickinson and Company Announces Executive ChangesBecton, Dickinson and Company announced that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently serves as senior vice president, deputy general counsel, and chief ethics andcompliance officer. Before joining BD, she was vice president and general counsel of North America for Sandoz Inc. and prior to that served as vice president and associate general counsel at Catalent Pharma Solutions. Quinn holds a Juris Doctor from Villanova University and a Bachelor of Arts in Political Science from Colgate University. As part of the leadership transition, BD also announced that effective February 3, Ami Simunovich, executive vice president and chief regulatory officer, will report directly to Polen and Public Affairs will report to Simunovich. Inaddition, Corporate Development will report to Chris DelOrefice, executive vice president and chief financial officer, bringing a closer alignment between Corporate Development and Corporate Strategy. Khichi, 55, is currently general counsel and executive vice president, Corporate Development, Public Affairs andRegulatory Affairs, which he has served as since 2017, when he joined BD through the acquisition of C. R. Bard. Prior to joining BD, Khichi was senior vice president, general counsel and secretary at C. R. Bard. Prior to Bard, he served as senior vice president, chief administrative officer and general counsel for Catalent Pharma Solutions.
お知らせ • Jan 06Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023Becton, Dickinson and Company announced that they will report Q1, 2023 results at 6:30 AM, US Eastern Standard Time on Feb 02, 2023
お知らせ • Dec 21Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023, at 13:00 US Eastern Standard Time. Location: The Biltmore Hotel Miami Coral Gables, 1200 Anastasia Ave, Coral Gables, Florida Florida United States Agenda: To elect as directors of the eleven nominees names attached in the proxy statement doe one year term; to consider the ratification of selection of independent registered public accounting firm; to consider the advisory vote to approve named executive officer compensation; and to discuss other related matters.
お知らせ • Feb 04Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022Becton, Dickinson and Company revised revenue guidance for the fiscal year 2022. The company now expects fiscal year 2022 revenues to be in the range of $19.55 billion to $19.75 billion, which reflects an increase of approximately $250 million compared to approximately $19.3 billion to $19.5 billion previously announced.
お知らせ • Feb 02Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A.Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A. on February 1, 2022. Cytognos' approximately 80 employees will join BD as a result of the acquisition. The transaction is expected to be immaterial to BD's fiscal 2022 financial results and Cytognos' financial results will be reported under the Biosciences business within the Life Sciences segment. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Cytognos, SL from Vitro S.A. on February 1, 2022.
お知らせ • Jan 09Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the BD Kiestra™ Identifa SystemBecton, Dickinson and Company announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Kiestra™ IdentifA system, which is designed to automate the preparation of microbiology bacterial identification testing. Identifying the microorganism that is causing an infection is a labor-intensive process. With the BD Kiestra™ IdentifA, the lab technician uses BD Synapsys™ informatics to select discrete bacterial colonies from a digital plate image. Sophisticated robotics then physically pick those selected organisms and prepare the sample for specific identification testing. By automating what are typically cumbersome manual steps, the BD Kiestra™ IdentifA may reduce the potential for human error when preparing samples for bacterial identification and produce more accurate diagnoses for patients. Streamlining processes also enables lab technicians to focus their time and expertise on higher-value tasks. BD Kiestra™ IdentifA is the only FDA-cleared solution that is available as part of a track-connected system for lab automation to support specimen preparation workflows for routine and challenging isolate types. The integration of the BD Synapsys™ Informatics solution with the BD Kiestra™ IdentifA, in combination with matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) mass spectrometry, can yield more rapid and accurate identification of bacteria and yeasts to aid clinician treatment decisions.
お知らせ • Dec 23BD Announces New Distribution and Retail Partners for Bd Veritor At-Home Covid-19 TestBD announced the BD Veritor At-Home COVID-19 Test is now available for purchase through Everly Health, a digital health company at the forefront of the virtual diagnostics-driven care industry, and Southeastern Grocers, parent company of Fresco y Más, Harveys Supermarket, and Winn-Dixie stores, a leading grocery store serving the southeastern United States. Also available for purchase on Amazon.com, the BD Veritor At-Home COVID-19 Test is the first at-home COVID-19 test to use a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Fresco y Más, Harveys Supermarket and Winn-Dixie stores now offer tests to consumers in all in-store pharmacy departments at more than 230 grocery store locations. Everly Health offers tests to businesses, government agencies and consumers through their subsidiaries, Everlywell and Everly Health Solutions. When purchased through Everly Health Solutions, the BD Veritor™ At-Home COVID-19 Test integrates seamlessly with Everly Health Solutions' proprietary COVID-19 platform to give organizations the ability to send at-home tests to individuals, securely view test results for both PCR and rapid tests purchased through the company and help manage all elements of a COVID testing program.
お知らせ • Dec 22Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc.Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc. on December 21, 2021. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Scanwell Health, Inc. on December 21, 2021.
お知らせ • Dec 18BD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core LabsBD (Becton, Dickinson and Company) announced it has expanded the BD COR™ System to include a new MX instrument for high-throughput molecular testing for infectious diseases. The new instrument and its first test for sexually transmitted infections have been CE marked to the IVD directive 98/79/EC. The new MX instrument is the final piece of the BD COR™ System, which also includes a PX instrument that can prepare diagnostic samples by automating appropriate pre-analytical processing steps and a GX instrument that can leverage the BD Onclarity™ HPV Assay with extended genotyping to screen for HPV infections. The MX instrument is built off the proven BD MAX™ System molecular PCR (polymerase chain reaction) technology platform, a medium-throughput system typically found in hospital labs, and BD intends to leverage the BD MAX™ System menu of infectious disease tests to create assays that can be performed in high-throughput central reference labs on the BD COR™ System. The first test available on the MX instrument is the BD CTGCTV2 for BD COR™ System, which is designed to use a single test to detect the three most prevalent non-viral sexually transmitted infections — Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV). In addition to CE mark, the BD CTGCTV2 for BD COR™ System assay was also included on the Australian Register for Therapeutic Goods (ARTG) following review by Australia's Medical Devices Regulator, the Therapeutic Goods Administration (TGA). The BD COR™ MX/PX System allows 1,700 specimens to be loaded, with onboard capacity for reagents and samples that provide more than six hours of unimpeded system processing and up to 1,000 sample results in 24 hours, eliminating multiple technologist interactions currently required per shift. The BD COR™ System integrates and automates the complete molecular laboratory workflow from sample processing to diagnostic test result. The BD COR™ PX instrument integrates and automates the sample workflow for diagnostic specimens and assays, preparing the samples by performing the appropriate pre-analytical processing steps and automatically delivering the samples to the MX or GX instruments for molecular analysis. The MX instrument will perform the analytical steps of the BD CTGCTV2 molecular assay, including extraction, amplification and detection. Additional assays for the MX module are in development. The GX module is exclusively used for HPV testing. The BD COR™ PX/GX System has been in use in Europe since 2019. The system is modular and scalable, and designed to address multiple needs within laboratories for expanding molecular testing and increasing test volumes. The system is particularly well-suited to laboratories requiring high throughput for sample results and high capacity, minimizing staff interactions. The system enables the processing of samples directly from liquid-based cytology vials and other BD sample collection devices, and the creation of molecular aliquot tubes and assay testing — automating labor-intensive and error-prone manual processes.
お知らせ • Dec 10Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd.Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd. on December 9, 2021. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Tissuemed Ltd. on December 9, 2021.
お知らせ • Dec 03Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc.Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc. on December 2, 2021. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Venclose, Inc. on December 2, 2021.
お知らせ • Aug 26+ 1 more updateBecton, Dickinson and Company Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver ResultsBecton, Dickinson and Company announced the U.S. Food and Drug Administration has issued an Emergency Use Authorization for the BD Veritor™ At-Home COVID-19 Test — the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results. The test does not require a prescription, a laboratory or a long wait for results. BD developed this new rapid, digitally read, lateral flow antigen self-test to make COVID-19 testing faster and easier for people to complete in the privacy and safety of their own homes. The test will initially be made available to businesses, schools and governments looking to provide a self-testing option for employees or students. The BD Veritor™ At-Home COVID-19 Test will use a simple, pain-free nasal swab and an easy-to-use mobile app from Scanwell Health that yields reliable test results in 15 minutes. The app is available on iOS and Android and provides step-by-step instructions on how to collect and transfer the nasal swab sample to the test stick. The mobile device's camera is then used to capture, analyze and interpret the results, which eliminates the human subjectivity of a visually read test. The BD Veritor™ At-Home COVID-19 Test is designed to be easily performed at home by people 14 years of age or older, using Scanwell Health's app to provide clear digital results in 15 minutes. The test can also be used for children as young as two years old with samples collected by an adult. The simple and straightforward testing experience includes a pain-free nasal swab, video instructions that guide users through each step and built-in timers so users can self-test with confidence.
お知らせ • Aug 12BD (Becton, Dickinson and Company) Announces the Launch of A New Benchtop Cell AnalyzerBD (Becton, Dickinson and Company) announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes. The new BD FACSymphony™ A1 Cell Analyzer is a fluorescence-activated cell analyzer that offers advanced research capabilities in a compact design, which helps improve access to instrumentation for complex scientific research to more labs. Fluorescence-activated cell sorter (FACS) technology enables the precise isolation of selected single cells from complex samples. This new BD cell analyzer offers researchers and scientists, regardless of their experience and level of expertise, access to proven technology to conduct a variety of flow cytometry experiments, helping them save time by using lab resources more efficiently and expand research capabilities in their own laboratories. This BD FACSymphony™ A1 Cell Analyzer features BD FACSymphony™ instrument technology with the flexibility to meet a broad spectrum of research needs from small particle research to 16-color immunophenotyping, along with industry-standard BD FACSDiva™ Software for streamlined workflows from system setup to data acquisition and analysis. The BD FACSymphony™ A1 Cell Analyzer joins the extended family of BD FACSymphony™ Cell Analyzers and Sorters and is an important addition to this comprehensive line up of flow cytometers to make powerful flow cytometry capabilities more accessible to researchers. The compact size of the system makes it ideal for individual laboratories with limited space. Researchers can perform independent detection of both large and small particles, such as extracellular vesicles on a single instrument using the optional BD® Small Particle Detector. It also enables larger laboratories to perform exploratory experiments without tying up free-standing cell analyzers needed for more complex, longer lead-time experiments.
お知らせ • Aug 06Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc.Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc. recently.
お知らせ • Jun 24BD Announces Expanded 510(k) Clearance for At-Home System for AscitesBD (Becton, Dickinson and Company) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the PeritX™ Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites. Ascites is a debilitating condition that causes the build-up of fluid in the abdomen. The PleurX™ Peritoneal Catheter System was introduced in 2005 for the drainage of malignant ascites. With the new, expanded indication, the system is being rebranded as the PeritX™ Peritoneal Catheter System to make it easier for physicians to navigate BD's portfolio of at-home drainage products. The PeritX™ Peritoneal Catheter System is the first and only FDA indicated tunneled catheter for the drainage of malignant and non-malignant ascites and for the palliation of symptoms related to recurrent ascites. Ascites is a condition in which fluid collects in spaces within the abdomen. It can make ordinary daily activities more challenging. The fluid may also move to the chest and surround the lungs, making breathing more difficult.
お知らせ • May 27Becton, Dickinson and Company Launches Urine Culture ApplicationBecton, Dickinson and Company announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis. Designed using artificial intelligence and leveraging the quality of BD BBL plated media, the application uses digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean caught and catheterized samples. The BD Kiestra system's intelligent incubation and imaging device uses high-throughput robotics to perform time series imaging, coupled with machine learning so that plates with no significant growth can be released for disposal and plates with significant growth automatically go into a queue for clinician analysis. In many labs, urine cultures make up a significant part of the daily workload however, the majority of those samples have no growth or non-significant growth and don't require any additional work-up. Batch review of large volumes of plates with non-significant growth and release can help medical laboratorians focus their time and expertise on more clinically relevant tasks. Powered by BD Synapsys informatics solution, the BD Kiestra Urine Culture application may help improve lab efficiency and enhance quality by providing diagnostically relevant, standardized images for interpretation by laboratory staff. The new Urine Culture app can be used with both standalone BD Kiestra ReadA systems as well as track-based BD Kiestra laboratory automation solutions.
お知らせ • May 26+ 1 more updateBecton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC.Becton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC in November 2020. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC in November 2020.
お知らせ • May 14Becton, Dickinson and Company Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal SamplesBecton, Dickinson and Company announced the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC. The new claim allows laboratories and facilities to process self-collected samples via a BD diluent tube using the BD Onclarity™ HPV Assay on either the BD Viper™ LT or the BD COR™ System. The BD Viper™ LT is in use globally and the BD COR™ System, launched last year, is in use across Europe. At-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening. Over half of all cervical cancers are diagnosed in women who have never been screened or have not been screened in the previous five yearsii, a situation that has been compounded by the recent global pandemic. Persistent infection with HPV is the cause of virtually all cases of cervical canceriii. Current estimates indicate that every year in Europe, more than 61,000 women are diagnosed with cervical cancer and nearly 26,000 die from the disease,iv making cervical cancer the second-most common female cancer deaths in women aged 15 to 44 and the ninth-most frequent cancer among women overall The BD Onclarity™ HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis and provides genotyping information from specimens collected for cervical cancer screening purposes. The BD Onclarity™ HPV Assay includes genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, 35/39/68 and 56/59/66.
お知らせ • May 07+ 1 more updateBD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth MarketsBecton, Dickinson and Company announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes Care business as an independent, publicly traded company(NewCo). BD believes the spinoff of the Diabetes Care business will create long-term value for BD shareholders and create a platform to continue to enhance the tools provided to people with diabetes. The transaction is expected to create two, independent companies with: Enhanced focus on strategic, operational and financial drivers to accelerate revenue growth; Optimized product portfolios to better meet customer and patient needs; More efficient resource and capital allocation to pursue each company's strategic goals. BD management expects that, as a separate independent entity, NewCo will be better positioned to pursue its strategic priorities, build on its current leadership positions in the diabetes care market, and attract new investors. NewCo's margin structure, positive cash flows and anticipated capital structure are expected to provide financial flexibility to pursue increased investments in organic and inorganic growth opportunities. NewCo is also expected to use its publicly traded stock to more effectively attract, incentivize and retain qualified talent. Following the spinoff, BD will maintain category leadership positions across its portfolio in the BD Medical, BD Life Sciences and BD Interventional segments. BD Medical, which includes the Diabetes Care business, will continue to be the global leader in end-to-end medication management solutions with its BD Alaris™ brand of infusion pumps, BD Pyxis™ brand of medication and supply dispensing solutions, BD HealthSight™ data and analytics platforms and its breadth of medication delivery devices. It will also continue to be the global leader in prefilled injectable delivery devices through its innovative pre-fillable syringes, self-injection systems, safety systems and needle technologies. The spinoff does not impact BD's ability to fulfill its orders related to COVID-19 mass vaccination campaigns. BD Life Sciences is a global leader of solutions from discovery to diagnosis, continually advancing science and clinical outcomes across infectious disease and cancer. Its product offerings include market leading specimen collection and management, and microbiology automation and testing solutions. BD is a leading provider of high-quality flow cytometry and single-cell genomics solutions for scientific research and clinical laboratories. The Life Sciences segment continues to play a critical role in both molecular and rapid antigen testing during the COVID-19 pandemic. The BD Interventional segment is also a global leader, advancing the treatment of high-burden diseases like peripheral arterial and venous disease, cancer, and end-stage renal disease. It also focuses on developing innovative surgical, endovascular, urological and critical care interventions that not only meet clinical needs but also deliver value to health systems and improve patients' lives. The decision to pursue the spinoff of the Diabetes Care business demonstrates BD's strong ongoing commitment to the company's BD 2025 strategy, which includes its three strategic pillars of Grow, Simplify and Empower. BD intends to maintain its investment grade rating while investing in growth opportunities focusing on higher growth market categories. BD will also continue to increase its R&D investments and strengthen its pipeline across three innovation themes, which include applying smart devices, robotics, analytics and artificial intelligence to improve care processes; enabling new care settings to enhance patient experience and lower costs; and investing to improve diagnosis and treatment of chronic disease. BD expects the spinoff to be accomplished through a distribution of stock in NewCo to BD shareholders. The spinoff is expected to be tax-free for U.S. federal income tax purposes, except to the extent of any cash received in lieu of fractional shares. BD does not expect the spinoff to impact its current dividend. The transaction is also expected to be completed in the first half of calendar year 2022, subject to the satisfaction of customary conditions, including final approval from the BD Board of Directors, regulatory approvals and the effectiveness of a Form 10 registration statement that will be filed with the SEC. There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed at all.
お知らせ • Apr 30+ 1 more updateBD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular FistulaBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV. CONNECT-AV is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQTM EndoAVF System for 24 months. The study's dual primary effectiveness endpoints are the percentage of subjects dialyzing using successful 2-needle cannulation for at least 75% of the dialysis sessions over a continuous 28-day period at 6 months, and the subjects maintaining primary patency at 6 months. The primary safety endpoint is freedom from device and procedure-related serious adverse events through 30 days. The trial is expected to enroll 280 participants in the United States. CONNECT-AV is one of two post-market studies of the WavelinQ™ EndoAVF System. The second study, WAVE-Global is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQ™ EndoAVF System for 24 months. The WAVE-Global primary endpoints are the number of interventions needed post creation to facilitate and/or maintain AV fistula use at 6 months, and the proportion of participants with freedom from Clinical Events Committee adjudicated device- or procedure-related serious adverse events at 30 days. The trial is expected to enroll 150 participants globally (outside of the United States).
お知らせ • Apr 29Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2021The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to holders of record on June 9, 2021. The indicated annual dividend rate is $3.32 per share.
お知らせ • Apr 27BD Announces FDA 510(k) Submission for BD Alaris™ SystemBD (Becton, Dickinson and Company) announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alaris™ System, the most widely used infusion pump in acute care hospitals across the United States. The 510(k) submission is intended to bring the regulatory clearance for the BD Alaris™ System up to date, implement updated features and address open recall issues, including through a new version of BD Alaris™ System software that will provide clinical, operational and cybersecurity updates. The BD Alaris™ System allows clinicians to deliver medications, fluids and blood products through a single integrated platform that includes large volume pumps, syringe pumps and patient-controlled analgesia (PCA) modules for adult, pediatric and neonatal patients.
お知らせ • Mar 11BD Announces Collaboration with ImageMover for Rapid Antigen Test ReportingBD announced an agreement with ImageMover, a software platform that automates and simplifies medical data collection and management, to offer a companion mobile app that enables more streamlined reporting of SARS-CoV-2 antigen testing results performed on the BD Veritor™ Plus System at everyday testing locations, such as schools and businesses. The ImageMover app is available immediately for BD Veritor™ Plus System customers. COVID-19 testing in everyday settings presents challenges in managing test subject demographics and results. The ImageMover app enables organizations performing point-of-care testing to efficiently capture required demographic details of those being tested, upload COVID-19 test results, report results to appropriate stakeholders and automate reporting to federal and state agencies. While the BD Veritor™ Plus System has built-in functionality to allow for data sharing to electronic health records through the BD Synapsys™ Informatics platform, that functionality requires an information technology infrastructure common to diagnostic testing locations in health care facilities such as hospitals, doctor's offices and urgent care centers. The addition of the ImageMover app provides the benefits of seamless and secure data sharing for everyday locations that don't have a health care information technology platform in place. The ImageMover app coordinates with the BD Veritor™ Plus System to upload testing results for streamlined reporting and significantly reduced manual documentation. The app is compliant with patient privacy requirements under the Health Insurance Portability and Accountability Act of 1996 (HIPAA). For traditional acute care settings, the optional BD Synapsys™ Informatics solution will continue to deliver automated result reporting, provide streamlined CARES Act and other Health & Human Services-mandated reporting functionality, and offer analytics and reports to support clinical and operational decision-making. The ImageMover app differs from BD's previously announced collaboration with Scanwell Health, which was created to develop a lateral flow antigen test to be paired with the Scanwell Health mobile app for at-home use. The Scanwell Health app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample, perform the test and use the mobile device's camera to analyze and interpret results in the home. The ImageMover app still requires the use of the BD Veritor™ Plus System to read the results of the test, but it provides a more streamlined reporting tool for testing locations that don't have a health care IT infrastructure.
お知らせ • Mar 05Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc.Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc. on March 4, 2021. BD will look forward to welcoming GSL's approximately 20 full-time associates, headquartered in Vancouver, Washington. Andy Dixon, Taylor Will and Michael Mahoney of Harris Williams LLC acted as financial advisor to GSL Solutions in the transaction. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of GSL Solutions, Inc. on March 4, 2021.
お知らせ • Feb 23BD and Scanwell Health Announces Collaboration for At-Home Rapid Test for COVID-19BD (Becton, Dickinson and Company) and Scanwell Health announced a collaboration to create an at-home rapid test for SARS-CoV-2 using a BD antigen test and the Scanwell Health mobile app. As part of the collaboration, BD plans to produce a lateral flow antigen test and pair it with the Scanwell Health mobile app. The app is expected to provide step-by-step instructions on how to collect and transfer a nasal swab sample and use the mobile device's camera to analyze and interpret results. The test result will be displayed onscreen, and the companies are also planning to develop functionality to assist in automated reporting to public health agencies. This approach is intended to provide an efficient and scalable rapid antigen home testing solution. BD has been on the forefront of the COVID-19 response providing innovative solutions for immunology research, molecular- and antigen-based diagnostics, devices that aid in therapeutics and injection devices for vaccine administration.
お知らせ • Feb 13BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single TestBD (Becton, Dickinson and Company) announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and Influenza A+B that can return results in two to three hours. The new test also has been CE marked to the IVD Directive (98/79/EC). The new EUA includes updated information in the test's instructions for use that addresses variants of the SARS-COV-2 virus, including variants from the U.K. and South Africa. A computer analysis showed that 99.9% of the genetic sequences of the these variants are an identical match to at least one of the two molecular targets for the testi. This ability to detect these new variants also applies to the standalone SARS-CoV-2 test for the BD MAX™ System. The BD® SARS-CoV-2/Flu assay is run on the BD MAX™ System and distinguishes between SARS-CoV-2 and Influenza A+B, providing a positive or negative result for each virus using a single specimen. The BD MAX™ System, a molecular diagnostic platform, is already in use at thousands of laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The BD® SARS-CoV-2/Flu for BD MAX™ System kits are now available for order in the United States and Europe. The test is the latest addition to the company's comprehensive COVID-19 diagnostics response. In October 2020, BD announced the CE mark for the CerTest Biotec VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit, which allows BD MAX™ System users to combine as a single test the VIASURE Flu A, Flu B & Respiratory Syncytial Virus (RSV) Real Time PCR Detection Kit and report concurrently. This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection of nucleic acid from SARS CoV-2, influenza A virus and influenza B virus and not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
お知らせ • Feb 05Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021Becton, Dickinson and Company revised earnings guidance for the fiscal year 2021. The company now expects fiscal year 2021 revenues to grow 12% to 14% on an as reported basis and 10% to 12% on a currency-neutral basis. This compares to the company’s prior guidance of high single to low double-digit revenue growth on a reported basis.
お知らせ • Feb 02Becton, Dickinson and Company Announces New Clinical Data Found Robust Evidence Using A Vascular Care SolutionBD (Becton, Dickinson and Company) announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for patients requiring peripheral intravenous catheters (PIVCs). The results of the CLEAN3 trial1, published in The Lancet Infectious Diseases, showed the use of the BD vascular care solution resulted in fewer PIVC failures compared with the standard group (34.8% vs. 47.5%, respectively) and extended the median time between catheter insertion and failure (50.4 hours vs 30.0 hours, respectively). PIVC failure was defined as any premature removal of PIVC before end of treatment – other than for routine replacement – and included phlebitis, infiltration, occlusion, dislodgment, local infection and catheter-related bloodstream infection (whichever occurred first). The CLEAN3 trial also evaluated skin antiseptics with 2% chlorhexidine-gluconate (CHG) 70% isopropyl alcohol (IPA) single use, sterile applicator versus 5% povidone iodine (PVI) 69% ethanol applied with sterile gauze in preventing infectious complications related to the use of PIVCs (catheter colonization: 0.9% vs. 16.9%, respectively; local infection: 0% vs. 1.2%, respectively). The trial, which involved approximately 1,000 patients from nine different medical wards within a single university hospital (Poitiers University Hospital, France), evaluated PIVC failure rates by comparing the BD vascular care solution for PIVCs, which included an integrated PIVC (BD Nexiva™), a positive displacement needle-free connector (BD MaxZero™), a disinfecting cap (BD PureHub™) and a sterile prefilled flush syringe (BD PosiFlush™) – compared with a standard group, which included a straight safety PIVC (BD Insyte™ Autoguard™ BC Winged), extension set three-way stopcock; the PIVCs were continuously infused with saline or polyionic solution, by gravity.
お知らせ • Jan 28+ 1 more updateBecton, Dickinson and Company Announces Board ChangesBD (Becton, Dickinson and Company) announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, effective April 28, 2021. Polen will succeed Vincent A. Forlenza, who will retire from BD at that time. Polen joined BD in 1999, and has held a variety of leadership roles at numerous business units. He was appointed president of BD in April 2017, was named chief operating officer in October 2018 and became CEO in January 2020.
お知らせ • Jan 26Becton, Dickinson and Company Announces the Publication of Peer-Reviewed Study That Shows Antigen Test May Be More Selective Than Polymerase Chain Reaction Molecular TestsBecton, Dickinson and Company announced the publication of a peer-reviewed study that shows BD's antigen test may be more selective than PCR (polymerase chain reaction) molecular tests at detecting people who are contagious and able to spread COVID-19 disease. The study compared antigen and PCR test results to positive results using a viral cell culture test. Viral growth in the cell culture test indicates the presence of live virus in the patient sample, which may indicate the presence of infectious virus at the time the sample was taken. If no growth is present in the viral cell culture test, it is likely that there wasn't enough viable virus for the patient to be contagious at the time the sample was taken. Out of 38 positive PCR result specimens tested, only 28 were positive using the cell culture technique. The antigen tests, conducted using the BD Veritor™ Plus System, were positive in 27 of the 28 cell culture positive tests. This data suggests that 10 of the 38 PCR positive results were potentially identifying non-infectious individuals, meaning PCR detected viral RNA fragments or small amounts of intact SARS-CoV-2 virus and that the patient wasn't actually contagious at the time the sample was taken. However, the BD antigen test agreed with all but one cell culture positive test. Diagnosing and isolating contagious people has been the primary goal for testing during the pandemic, followed by contact tracing and testing.
お知らせ • Jan 13Becton, Dickinson and Company to Report Q1, 2021 Results on Feb 04, 2021Becton, Dickinson and Company announced that they will report Q1, 2021 results on Feb 04, 2021
お知らせ • Dec 19Becton, Dickinson and Company, Annual General Meeting, Jan 26, 2021Becton, Dickinson and Company, Annual General Meeting, Jan 26, 2021, at 13:00 US Eastern Standard Time. Agenda: To consider the election as directors of the thirteen nominees named in the attached proxy statement for a one-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; to consider a shareholder proposal seeking to lower the ownership threshold required to call a special shareholders meeting, if properly presented at the meeting; and to consider such other business as may properly come before the meeting, or any adjournment or postponement thereof.
お知らせ • Dec 18+ 2 more updatesBecton, Dickinson and Company Surpasses 1 Billion Injection Device Orders in Support of Covid-19 Vaccination Efforts Around the WorldBD announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to support global COVID-19 vaccination planning efforts. This milestone reflects 400 million dose units committed to countries across Europe, including Belgium, France, Germany, Netherlands, Spain and the United Kingdom, among several others. It also reflects governments around the world, including the United States, Australia, Canada and Saudi Arabia, as well as non-governmental organizations supporting vaccine deployment for developing countries. Shipments are already underway and more than 300 million injection devices have been delivered around the world to date, including 125 million in Europe, with the remaining orders to be delivered between now and the end of 2021 to support vaccine administration. A vast majority of the needles and syringes for Europe are being produced in two of BD's manufacturing facilities in Europe. These devices are then shipped to governments or appointed distribution partners where they will then be distributed to health care facilities based on each country's individual distribution and allocation strategy. BD continues to be in discussions with governments and non-governmental organizations on the need to place orders immediately for delivery later in calendar year 2021 and 2022. The company continues to closely plan supply capabilities to ensure maximum volumes can be dedicated to COVID-19 efforts while minimizing disruption for routine health care and annual flu vaccination and childhood immunization programs. In addition to supporting immediate efforts for COVID-19 vaccination readiness, BD is also working on multiple fronts to help ensure the global community is prepared for future pandemic vaccination efforts by: Partnering with the U.S. government on a $70 million capital project to further expand BD's operations and manufacturing capacity in Nebraska. The new capacity is expected to be online in summer 2021 and once completed, the federal government will have priority access to hundreds of millions of injection devices to support vaccination efforts for COVID-19 and future pandemics. Investing approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems across its six global manufacturing locations and add a new manufacturing facility in Europe. This will allow for continued growth of new injectable drugs and vaccines, but also provide surge capacity for increased pre-fillable syringe demand during times of pandemic response. Actively engaging with med-tech associations and research groups to address challenges, solutions and further innovation in support of a more sustainable future vaccine ecosystem. In addition to ramping up manufacturing of needles and syringes, BD has been working closely with governments and multilateral organizations around the world to expand access to diagnostic testing and support treatment of COVID-19 patients. The company has supplied health care providers globally with millions of products used in of the fight against COVID-19, including swabs for flu and COVID-19 testing, rapid molecular diagnostic tests on the BD MAX™ System, 15-minute point-of-care antigen testing on the BD Veritor™ Plus System, infusion pumps, infusion sets and catheters. BD Biosciences instruments are also being used by researchers around the world to better understand the human immune response to COVID-19.
お知らせ • Nov 18Becton, Dickinson and Company Announces Board ChangesOn November 13, 2020, Patrick K. Kaltenbach, Executive Vice President and President, Life Sciences Segment of Becton, Dickinson and Company (BD"), informed BD that he plans to leave BD, effective January 21, 2021, to pursue an executive leadership position based in Europe, bringing him closer to his family. As previously announced, Dave Hickey, currently President of BD's Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President, Life Sciences Segment, effective January 1, 2021. BD had previously announced plans to have Mr. Kaltenbach serve as BD's Chief Technology Officer, beginning January 1, 2021. As a result of Mr. Kaltenbach's upcoming departure from BD, John DeFord, Executive Vice President and Chief Technology Officer, will postpone his previously announced retirement and continue to lead the company's innovation strategy and R&D pipeline until May 28, 2021 or earlier when a successor is identified.
お知らせ • Nov 13Becton, Dickinson and Company (NYSE:BDX) acquired Medical Business assets of Cubex LLC.Becton, Dickinson and Company (NYSE:BDX) acquired Medical Business assets of Cubex LLC on November 12, 2020. Becton, Dickinson and Company is excited to welcome approximately 40 Cubex LLC associates into the BD family. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Medical Business assets of Cubex LLC on November 12, 2020.
お知らせ • Nov 11+ 1 more updateBD Announces Canadian Government Order of More Than 7 Million Portable, Rapid Point-of-Care Antigen Tests to Detect SARS-CoV-2 in 15 minutesBD announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been authorized for use by Health Canada under Interim Order. This authorization has been accompanied by an order from the Canadian government for 7.6 million tests through March 2021 to support Canada's planning for an advanced COVID-19 testing strategy. The new test delivers results in approximately 15 minutes on an easy to use, portable instrument, which is a critical improvement in turnaround time for COVID-19 diagnostics, because it provides real time results and enables decision making while the patient is still onsite. This test is designed to be performed at the point-of-care, reducing the burden on testing laboratories. The test uses a mid-nasal swab to collect patient samples, which is less invasive for the patient than nasopharyngeal sample collection. The test, which received Health Canada authorization in early October, has been available in the United States since July through an Emergency Use Authorization from the U.S. Food and Drug Administration (FDA). The test uses the BD Veritor™ Plus System, which is already in use in Canada to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. The BD Veritor™ Plus System, which has a slightly larger footprint than a mobile phone, offers an easy-to-use workflow that makes it an ideal solution for point-of-care settings. It also offers customers traceability and reporting capabilities through the optional BD Synapsys™ informatics solution. BD has also been supporting SARS-CoV-2 molecular testing (RT-PCR) in Canadian labs on the BD MAX™ System.
お知らせ • Nov 04Becton, Dickinson and Company Receives Order from Dutch Ministry of Health for More Than 9 Million 15-Minute Covid-19 Antigen TestsBecton, Dickinson and Company announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid, point-of-care, SARS-CoV-2 antigen tests for use on the BD Veritor™ Plus System, which detects SARS-CoV-2 in symptomatic patients in approximately 15 minutes. The first 1.2 million units will be delivered by mid-November. This is the first government contract in Europe for this test, which was CE marked to the IVD Directive (98/79/EC) in September. The Dutch Ministry of Health increased its initial order by 8 million assays to improve testing capacity. BD expects the order to be fulfilled by June 2021. The BD Veritor™ Plus System is a portable, easy-to-use device that makes it an ideal solution for point-of-care settings. The BD Veritor™ Plus System is already in use across Europe to detect Influenza A+B, Respiratory Syncytial Virus (RSV), and Group A Strep. The SARS-CoV-2 assay has been available in the United States since July through an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
お知らせ • Oct 06FDA 510(k) Clearance for BD Facslyric Flow Cytometer with Newly Integrated BD Facsduet Sample Preparation SystemBecton, Dickinson and Company announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ Flow Cytometer with the Integrated BD FACSDuet™ Sample Preparation System. The new integrated system enables clinical laboratories to fully automate the sample to answer process and improve their efficiency by reducing errors and limiting the manual user interactions required to run assays on the BD FACSLyric™ Flow Cytometer. The BD FACSDuet™ Sample Preparation System builds new capabilities into the BD portfolio of clinical flow cytometry solutions offering a pre-analytical system, that combined with the BD FACSLyric™ Flow Cytometer is the first truly walkaway sample-to-answer solution for clinical labs. Physical integration between the BD FACSDuet™ Sample Preparation System and the BD FACSLyric™ Flow Cytometer allows technicians to load samples and reagents onto the BD FACSDuet™ Sample Preparation System and obtain results once the samples are acquired and analyzed on the BD FACSLyric™ Flow Cytometer. Data integration using the BD FACSLink™ Middleware Solution offers bidirectional communication between the instruments and connectivity with laboratory information systems (LIS). Automation solutions for flow cytometry such as the BD FACSDuet™ and BD FACSLyric™ Complete Sample-to-Answer Solution helps to improve accuracy and standardization from instrument-to-instrument and operator-to-operator, enhancing throughput and providing consistent results that clinicians depend on to inform patient care.
お知らせ • Oct 03Becton, Dickinson and Company to Report Q4, 2020 Results on Nov 05, 2020Becton, Dickinson and Company announced that they will report Q4, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020
お知らせ • Oct 01Becton, Dickinson and Company Announces CE Mark of Portable, Rapid Point-Of-Care Antigen Test to Detect SARS-CoV-2 in 15 MinutesBecton, Dickinson and Company announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the IVD Directive (98/79/EC). The new test delivers results in 15 minutes on an easy-to-use, portable instrument, which is a critical improvement in turnaround time for COVID-19 diagnostics, because it provides real-time results and enables decision-making while the patient is still onsite. The company expects commercial availability of this new assay at the end of October for countries in Europe that recognize the CE mark. The test, which has been available in the United States since July through an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA), uses the BD Veritor™ Plus System, which is already in use across Europe to test for conditions such as Group A Strep, influenza A+B and Respiratory Syncytial Virus (RSV). The BD Veritor™ Plus System, which is slightly larger than a mobile phone, offers an easy-to-use workflow that makes it an ideal solution for point-of-care settings. It also offers customers traceability and reporting capabilities through the optional BD Synapsys™ informatics solution. The European Centre for Disease Prevention and Control (ECDC) recently released guidance that all patients with acute respiratory symptoms should be tested for both SARS-CoV-2 and influenza A+B in parallel during flu season1. The BD Veritor™ Plus System can test for both infections on the same platform. BD is leveraging its global manufacturing network and scale to produce 8 million SARS-CoV-2 antigen tests per month by October and expects to produce 12 million tests per month by March 2021. All BD SARS-CoV-2 diagnostic products have regulatory authorizations in the markets where they are sold. European customers interested in BD diagnostic solutions for SARS-CoV-2 should visit bd.com/VeritorSystem-EU [1] or contact BD's local customer service. The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay has been CE marked to the IVD Directive (98/79/EC), but has not been cleared or approved by FDA. The test has been authorized by FDA under an EUA for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay is not authorized for use by consumers or for at-home use.
お知らせ • Sep 24BD Submits Pre-Market Approval Supplement to the U.S. Food and Drug Administration for the use of the ThinPrep® Pap Test™ PreservCyt® SolutionBD announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the use of the ThinPrep® Pap Test™ PreservCyt® Solution vial as an approved sample type for its BD Onclarity™ HPV Assay. The PMA supplement would expand the sample claims that can be used in addition to the BD SurePath™ vial for the detection of human papillomavirus (HPV) using the BD Onclarity™ HPV Assay. The submission includes performance data for the BD Viper™ LT and the BD COR™ Systems. An additional supplement was submitted in January 2020 to seek approval for the BD Onclarity™ HPV assay on the BD COR™ System and the BD SurePath™ Liquid Based Cytology vial.
お知らせ • Sep 22Becton, Dickinson and Company Announces FDA Classifications for August 4th Recalls of BD Alaris System Hardware for Keypads, Incorrect Module Types And/Or Sizes, and Channel ErrorBecton, Dickinson and Company provided an update on previously announced voluntary recalls of the BD Alaris System. Three of the recalls, which BD announced on Aug. 4, 2020, have been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means that FDA has determined that there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. One of the situations was designated as a Class II recall, which means use of the product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. This FDA classification does not change the guidance BD provided in the company's Aug. 4th recall announcements to customers. BD initiated the voluntary recalls to notify customers of the potential for four hardware situations that may result in the infusion pump not operating as expected. BD has provided instructions to correct and/or mitigate the situations. The four recalls include: Alaris PC Unit Model 8015 Front Case with Keypad Replacement Kits (Recall 1 'Class I): The pump module keypad may exhibit keys that are unresponsive or stuck as a result of fluid ingress, potentially resulting in a delay to the start of infusion, interruption of infusion or inability to titrate medication. Alaris Pump Module Model 8100 Front Case with Keypad Replacement Kits (Recall 2 'Class I): Pump Module keypad may exhibit keys that are unresponsive or stuck as a result of fluid ingress, potentially resulting in a delay to the start of infusion or interruption of infusion. BD Alaris Syringe Module Model 8110 and PCA Module Model 8120 (Recall 3 - Class I): The Alaris PC unit may display incorrect syringe type and/or syringe sizes. This could potentially result in delays in infusion, under-infusion or over-infusion. BD Alaris EtCO2 Module model 8300 channel error (Recall 4 'Class II). Infusion pump component defect may result in interruption of patient monitoring. Affected Products: Recall 1: BD Alaris PC Unit model 8015 (manufactured from April 7, 2017 to present). PC Unit Front Case with Keypad Replacement Kits: TC10008389 ASSY CASE FRONT W/KEYPAD 8015LS; TC10010217 ASSY FRT CASE W/KEYPAD 8015 M2; TC10012515 ASSY FR CASE W/KEYPAD 8015 M2; TC10013702 ASSY, CASE, FRONT W/KEYPAD, 8015LS; TC10013664 ASSY FR CASE W/KEYPAD 8015 M2. Recall 2: BD Alaris Pump Module Model 8100 (manufactured from December 1, 2016 to January 23, 2019); Pump Module Door Assembly Replacement Kits (labeled with a date prior to January 25, 2019); Affected part numbers: 49000239; 49000346; 49000438; 49000439. Recall 3: BD Alaris Syringe Module Model 8110 (manufactured from March 1, 2010 to present); BD Alaris PCA Module Model 8120 (manufactured from March 1, 2010 to present); Syringe/PCA Sizer Sensor Replacement Kit (manufactured from March 1, 2010 to present); Affected part number: 12278652. Recall 4: Alaris EtCO2 Module, Model 8300 (manufactured from January 5, 2018 to January 4, 2019). Note that some affected devices may be branded under the CareFusion name.
お知らせ • Jul 31Becton, Dickinson and Company (NYSE:BDX) acquired Straub Medical AG.Becton, Dickinson and Company (NYSE:BDX) acquired Straub Medical AG on April 20, 2020. Martin Frey, Dennis Gödde, Yves Sewo and Andrina Schmitz of PwC Corporate Finance Switzerland acted as a financial advisors to the shareholders of Straub Medical AG. Daniel Daeniker, Daniel Hasler, Stefan Oesterhelt, Luca Dal Molin, Richard Stäub, Katrin Ivell and Claudia Suter of Homburger AG acted as legal advisors to Becton, Dickinson and Company. Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Straub Medical AG on April 20, 2020.
お知らせ • Jul 04Becton, Dickinson and Company(NYSE:BDX) dropped from Russell 1000 Growth-Defensive IndexBecton, Dickinson and Company(NYSE:BDX) dropped from Russell 1000 Growth-Defensive Index